For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Cagrilintide

Also known as: NN9838

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.

Where to buy · live market data

Who's worth your money for Cagrilintide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 31 scored sellers

$5.25/mg

$1050 · 200mg · 99.7% purity

Best value after code

$1.98/mg effective with 10% code

$2.20/mg

$22.00 · 10mg

no COAs yet
Buy Code merit · 10% off

Most tested

10 independent COAs on file

$8.80/mg

$44.00 · 5mg · 99.9% purity

Average price

$11.80/mg

Sellers

52

45-day trend

-14.4%

45 of 52 sellers have a current price· 5 stale hidden· 9 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Cagrilintide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Cagrilintide

CAS

1415456-99-3

Molecular formula

C194H312N54O59S2

Sequence

KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP

Typical dose range

0.3–4.5 mg once weekly subcutaneous (Phase 2); 2.4 mg/week maintenance in Phase 3 REDEFINE/REIMAGINE trials

Half-life

~159–195 hours (~7–8 days)

Independent evidence

COAs for Cagrilintide

150 third-party tests across 36 vendors. Each card links to the full report.

All 150 COAs for Cagrilintide →
Measured purity 98.9%–100.0% across 99 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.63 %
Sep 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by VoriLabs· batch CAGL-M2609-A

Aggregated · 3rd-party listing
99.89 %
Sep 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Moglabs· batch CAG-X-003

✓ Vendor-published
99.60 %
Sep 2026
BTLabs Moderate

For

Cagrilintide

by Sunrise Bioresearch· batch 6WSEGN4

COA on file
Aggregated · 3rd-party listing
99.84 %
Jul 2026
ILS Labs Strong

For

Cagrilintide

by Artisan Aminos· batch AA-CAG10-049

Aggregated · 3rd-party listing
99.57 %
Jul 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Peptide Plugs· batch 103-11-ZB

Aggregated · 3rd-party listing
99.72 %
Jul 2026
ILS Labs Strong

For

Cagrilintide

by Hydro Research Peptides· batch HR-2026-2608

Aggregated · 3rd-party listing
99.95 %
Jul 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG1006162026-02

Aggregated · 3rd-party listing
99.45 %
Jul 2026
ILS Labs Strong

For

Cagrilintide

by Ion Peptide· batch CGL5-06172026

✓ Vendor-published
99.95 %
Jul 2026
Janoshik Analytical Limited

For

Cagrilintide 10

by EZ Peptides· batch EZP-CAG10061620226-02

COA on file
Aggregated · 3rd-party listing
99.79 %
Jun 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Ion Peptide· batch CGL10-06252026

Aggregated · 3rd-party listing
99.56 %
Jun 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Ion Peptide· batch CGL5-06242026

Aggregated · 3rd-party listing
99.93 %
Jun 2026
Janoshik Analytical Limited

For

Cagrilintide

by Optima Supply· batch OS-2026-2806

Aggregated · 3rd-party listing
99.93 %
Jun 2026
Janoshik Analytical Limited

For

Cagrilintide

by Hydro Research Peptides· batch HR-2026-3852

Aggregated · 3rd-party listing
99.47 %
Jun 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Peptide Supply Co.· batch CGL10 06032026

Aggregated · 3rd-party listing
99.18 %
Jun 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Novaglo Research· batch 13060126CE

Aggregated · 3rd-party listing
100.00 %
Jun 2026
Prime Analytical Laboratories, LLC

For

Cagrilintide

by Soma Peptides· batch CAX0052658

Aggregated · 3rd-party listing
99.87 %
May 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG0505152026-12

✓ Vendor-published
99.89 %
May 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG0505152026-12

COA on file
✓ Vendor-published
99.89 %
May 2026
Janoshik Analytical Limited

For

Cagrilintide 5mg

by EZ Peptides· batch EZP-CAG05051520226-12

COA on file
Aggregated · 3rd-party listing
99.93 %
May 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Nox Amino· batch NA-CG0526-01

✓ Vendor-published
99.73 %
May 2026
TrustPointe Analytics Moderate

For

Cagrilintide

by Peptide Partners· batch SPL-3792

COA on file
Aggregated · 3rd-party listing
99.85 %
May 2026
ILS Labs Strong

For

Cagrilintide

by NG Peptide· batch CG10-12

Aggregated · 3rd-party listing
99.35 %
May 2026
ILS Labs Strong

For

Cagrilintide

by NG Peptide· batch CG05-08

Aggregated · 3rd-party listing
99.77 %
Apr 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Modern Research Peptides· batch RHKC6242

Research depth

20 citations indexed for Cagrilintide

All research on Cagrilintide →

Study · 2026

Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials

Background Overweight status, obesity, and diabetes represent significant socioeconomic burdens that require long-term management.

Study · 2026

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo

Background Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.

review · 2026

Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials

To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.

cohort · 2026

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials

Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.

rct · 2026

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study

Background Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.

rct · 2026

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide

Background and objectives Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes.